Communiqués Frazier Lifesciences Acquisition Corporation

Actions

FLAC

KYG3710A1058

Communiqués

24/11/22	NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib	AQ
23/11/22	NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease Patients	AQ
16/11/22	Frazier Lifesciences Acquisition Corporation shareholders approve business combination with NewAmsterdam Pharma Holding B.V	AQ
15/11/22	FRAZIER LIFESCIENCES ACQUISITION CORP : Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
15/11/22	Frazier Lifesciences Acquisition Corporation Shareholders Approve Business Combination with NewAmsterdam Pharma Holding B.V.	BU
15/11/22	Frazier Lifesciences Acquisition : shareholders approve business combination with NewAmsterdam Pharma Holding B.V.	PU
09/11/22	FRAZIER LIFESCIENCES ACQUISITION CORP Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
11/08/22	FRAZIER LIFESCIENCES ACQUISITION CORP Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
25/07/22	Frazier Lifesciences Acquisition : NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger - Form 8-K/A	PU
25/07/22	FRAZIER LIFESCIENCES ACQUISITION CORP Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K/A)	AQ
25/07/22	Frazier Lifesciences Acquisition : NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger - Form 8-K	PU
25/07/22	FRAZIER LIFESCIENCES ACQUISITION CORP : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
25/07/22	NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Transformative Oral Therapies for Major Cardiometabolic Diseases	BU
12/05/22	FRAZIER LIFESCIENCES ACQUISITION CORP Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
25/03/22	FRAZIER LIFESCIENCES ACQUISITION CORP Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
31/01/22	FRAZIER LIFESCIENCES ACQUISITION CORP Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q/A)	AQ
31/01/22	FRAZIER LIFESCIENCES ACQUISITION CORP - 10-K/A - Management's Discussion and Analysis of Financial Condition and Results of Operations.	AQ
26/01/22	FRAZIER LIFESCIENCES ACQUISITION CORP : Non-Reliance on Previous Financials, Audits or Interim Review (form 8-K)	AQ
09/11/21	FRAZIER LIFESCIENCES ACQUISITION CORP Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
09/08/21	FRAZIER LIFESCIENCES ACQUISITION : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
24/05/21	FRAZIER LIFESCIENCES ACQUISITION : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
24/05/21	FRAZIER LIFESCIENCES ACQUISITION : 10-K/A - Management's Discussion and Analysis of Financial Condition and Results of Operations.	AQ
24/05/21	FRAZIER LIFESCIENCES ACQUISITION CORP : Non-Reliance on Previous Financials, Audits or Interim Review (form 8-K)	AQ
26/03/21	FRAZIER LIFESCIENCES ACQUISITION : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ